Allan Gaw

9.5k total citations · 5 hit papers
68 papers, 7.0k citations indexed

About

Allan Gaw is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Allan Gaw has authored 68 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Surgery, 17 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Economics and Econometrics. Recurrent topics in Allan Gaw's work include Lipoproteins and Cardiovascular Health (40 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (17 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). Allan Gaw is often cited by papers focused on Lipoproteins and Cardiovascular Health (40 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (17 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). Allan Gaw collaborates with scholars based in United Kingdom, United States and Netherlands. Allan Gaw's co-authors include Chris J. Packard, James Shepherd, Ian Ford, Naveed Sattar, Stuart M. Cobbe, Peter W. Macfarlane, John Norrie, D S O’Reilly, J. Wouter Jukema and Edward Bollen and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Allan Gaw

64 papers receiving 6.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

2002 2.4k citations James Shepherd, Gerard J. Blauw et al. The Lancet profile →
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study

2003 1.2k citations Allan Gaw, Ian Ford et al. profile →
Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)

2001 689 citations Chris J. Packard, James Shepherd et al. profile →
Pravastatin and the Development of Diabetes Mellitus

2001 667 citations John Norrie, Stuart M. Cobbe et al. profile →
C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study

2002 597 citations John Norrie, Muriel Caslake et al. profile →

Peers

Countries citing papers authored by Allan Gaw

Since Specialization

Citations

This map shows the geographic impact of Allan Gaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Gaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Gaw more than expected).

Fields of papers citing papers by Allan Gaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan Gaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Gaw. The network helps show where Allan Gaw may publish in the future.

Co-authorship network of co-authors of Allan Gaw

This figure shows the co-authorship network connecting the top 25 collaborators of Allan Gaw. A scholar is included among the top collaborators of Allan Gaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Gaw. Allan Gaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study 2013 ·PLoS ONE ·Sarah Barry, Eleanor Dinnett, Sharon Kean, Allan Gaw, Ian Ford	38
2	Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 2009 ·Atherosclerosis ·Muriel Caslake, Chris J. Packard, Michele Robertson, Josephine Cooney, Jeanenne J. Nelson, Ian Ford, Allan Gaw, J. Wouter Jukema, Peter W. Macfarlane, David J. Stott, James Shepherd	20
3	Accuracy of patient recall of preoperative symptom severity (angina and breathlessness) at one year following aorta‐coronary artery bypass grafting 2009 ·Journal of Clinical Nursing ·Grace Lindsay, (unknown), Eric E. Brodie, Allan Gaw, Philip R. Belcher	8
4	Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk 2008 ·European Journal of Pharmacology ·Luis Miguel Blanco‐Colio, José Luis Martín‐Ventura, Carmen Gómez‐Guerrero, Xavier Masramón, Eduardo de Teresa, Csaba Farsang, Allan Gaw, Gianfranco Gensini, Lawrence A. Leiter, Anatoly Langer, Jesús Egido	35
5	Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration 2007 ·American Heart Journal ·Luis Miguel Blanco‐Colio, José Luis Martín‐Ventura, Eduardo de Teresa, Csaba Farsang, Allan Gaw, Gianfranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Jesús Egido	73
6	Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 2005 ·Atherosclerosis ·Allan Gaw, Heather Murray, Elizabeth A. Brown	32
7	Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 2005 ·Clinical Trials ·Eleanor Dinnett, (unknown), Jane A. Kent, (unknown), Karen McIntyre, E Anderson, Allan Gaw, (unknown)	20
8	Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participants 2004 ·Age and Ageing ·(unknown), (unknown), (unknown), Grace Lindsay, Allan Gaw	54
9	Statin therapy in the elderly 2004 ·Current Opinion in Lipidology ·(unknown), Allan Gaw	6
10	Statin Therapy in the Elderly 2003 ·Drugs & Aging ·(unknown), Allan Gaw, James Shepherd	20
11	A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics 2002 ·SHILAP Revista de lepidopterología ·Ian Ford, Gerard J. Blauw, Michael Murphy, James Shepherd, Stuart M. Cobbe, Edward Bollen, Brendan M. Buckley, J. Wouter Jukema, Michael E. Hyland, Allan Gaw, A. Margot Lagaay, Ivan J. Perry, Peter MacFarlane, John Norrie, A. Edo Meinders, Brian Sweeney, Chris J. Packard, Rudi GJ Westendorp, C. Twomey, David J. Stott, (unknown)	30
12	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: 2002 ·Controlled Clinical Trials ·Jerry Avorn, Josh Benner, Ian Ford, David A. Ganz, Allan Gaw, Robert J. Glynn, Jeanne Jackson, A. Margot Lagaay, Sebastian Schneeweiß, Thomas Walley, Philip S. Wang	5
13	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial breakdown → 2002 ·The Lancet ·James Shepherd, Gerard J. Blauw, Michael Murphy, Edward Bollen, Brendan M. Buckley, Stuart M. Cobbe, Ian Ford, Allan Gaw, Michael E. Hyland, J. Wouter Jukema, Adriaan M. Kamper, Peter W. Macfarlane, A. Edo Meinders, John Norrie, Chris J. Packard, Ivan J. Perry, David J. Stott, Brian Sweeney, (unknown), Rudi GJ Westendorp	2393
14	At what level of coronary heart disease risk should a statin be prescribed? 2000 ·Current Opinion in Lipidology ·Allan Gaw, Chris J. Packard	11
15	The design of a prospective study of pravastatin in the elderly at risk (PROSPER) 1999 ·The American Journal of Cardiology ·(unknown), Gerard J. Blauw, Michael Murphy, Stuart M. Cobbe, Edward Bollen, Brendan M. Buckley, Ian Ford, J. Wouter Jukema, Michael E. Hyland, Allan Gaw, A. Margot Lagaay, Ivan J. Perry, Peter W. Macfarlane, A. Edo Meinders, Brian Sweeney, Chris J. Packard, Rudi G. J. Westendorp, C. Twomey, David J. Stott	340
16	Predictors of plasma lipoprotein(a) concentration in the West of Scotland Coronary Prevention Study cohort 1999 ·Atherosclerosis ·Allan Gaw, (unknown), Elizabeth A. Brown, Ian Ford	11
17	Evidence based approach for the management of mixed hyperlipidaemia 1998 ·Atherosclerosis ·Allan Gaw	9
18	Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre‐eclampsia 1996 ·BJOG An International Journal of Obstetrics & Gynaecology ·Naveed Sattar, Allan Gaw, Chris J. Packard, Ian A. Greer	109
19	Molecular genetics of lipoprotein (a): new pieces to the puzzle 1994 ·Current Opinion in Lipidology ·Allan Gaw, Helen H. Hobbs	39
20	Lipids and Atherosclerosis Annual 2001 1988 ·Allan Gaw, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact